RATIONALE: Epithelial cell-derived cytokines are critical regulators in the pathogenesis of atopic dermatitis (AD). We examined mast cell expression of IL-33, ST2 and TSLPR in skin biopsies from patients with AD after intradermal allergen challenge. METHODS: Intradermal challenges with allergen and saline control were conducted in patients with moderate-to-severe AD. Punch biopsies were collected from the site of challenge 24 hours later, and stained with immunofluorescent antibodies to tryptase, IL-33, ST2, and TSLPR. Images were obtained and analysed by selecting regions of interest, and cells positive for the selected markers were expressed as cells per mm2 of the area examined. RESULTS: Compared to saline challenge, there was a significant increase in the number of tryptase-positive cells in the dermis (2-fold) and in the epidermis (3-fold) at 24 hours post-allergen (p<0.05). There was also an increase in the number of IL-33-positive cells in the dermis (2-fold) and epidermis (8-fold) after allergen compared to saline (p<0.05). Postallergen, most cells expressing IL-33 were tryptase-positive. Furthermore, there was a significant increase in the number of cells in the dermis and epidermis co-localizing tryptase and IL-33 after allergen compared to saline (p<0.05). In contrast, few tryptase-positive cells expressed ST2 and TSLPR, and expression of these receptors on tryptase-positive cells was not different between allergen and saline. CONCLUSIONS: Most cells expressing IL-33 post-allergen are tryptasepositive, and these cells that co-localize tryptase and IL-33 increase significantly after allergen challenge. These data suggest that mast cells are a major source of IL-33 in the skin following exposure to allergen. Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA, M alaga, Spain. RATIONALE: Galectin-9 is a molecule with a wide range of biological activities, including the control of some immunological processes. The inability to produce enough amount of Galectin-9 and/or an incorrect interaction with its receptor Tim-3, could be responsible for the uncontrolled increase of Th1 cells as happen in Drug-Induced Maculopapular Exanthema (DIMPE). Our aim was to analyze the role of Galectin-9 and Tim-3 in the proliferation of specific-effector T cells and Tregs in patients with DIMPE. ) by flow cytometry. Exogenous Galectin-9 was added, as well as antibodies aTim-3 to enhance or block the interaction respectively. Results were represented as proliferation index (PI). RESULTS: Higher PI was found when Th1, Tim-3 + Th1 and Tregs cells from allergic patients with DIMPE were cultured with the culprit drug compared to controls (p50.008, p50.012, p50.002 respectively). The addition of antibodies aTim-3 did not reduce the proliferation of any population. On the contrary, the addition of Galectin-9 reduced the proliferation of Th1 (p50.025) and Tim-3 + Th1 cells (p50.026), whereas increased the PI of Tregs (p<0.001). CONCLUSIONS: Galectin-9 has an important dual effect: its addition reduces the proliferation of specific-effector cells, whereas promotes the proliferation of Tregs in DIMPE patients. These data suggest that Galectin-9 could represent a therapeutical candidate able to control the disease.
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NFkB transcription factor binding is altered at many Atopic Dermatitis disease loci Amy Eapen, MD -8 ). Greater than 95% of these associations are in non-coding regions of the genome; we thus hypothesize that specific transcription factors (TF) are enriched at AD risk loci. METHODS: We applied our computational tools RELI and CIS-BP to identify enriched binding of transcription factors to disease risk loci and predict genetic variants that will alter transcription factor binding sites, respectively. RESULTS: After linkage disequilibrium expansion (5,102 variants at 80 loci), 24 independent NFkB (RELA, NFKB1, REL, NFKB2) chromatin immunoprecipitation datasets demonstrated enriched binding at AD risk loci (p55.73x10 -9 -3.43x10 -30 ), collectively overlapping 280 AD risk variants. Pathway analysis of genes near variants overlapped by NFkB revealed enrichment for numerous immunological gene sets including MHC class II receptor activity, positive regulation of immune system, and cytokine signaling (IL13, TNFSF4, IL6R) (adjusted p<0.005). 178 genes near AD risk variants overlapped by NFkB are eQTLs including IL13, IL5, IL18R1, IL18 RAP, and IL6R, and 12 different MHC class II genes across numerous cell types (e.g. HLA-DQB1 p510 -125 in skin,1.1-fold effect size). Based on the DNA sequence of the alleles and NFkB binding motif models, we expect allele-dependent NFkB binding at eight of the overlapped SNPs. CONCLUSIONS: These data are consistent with common genotypedependent transcriptional control mechanisms operating across multiple AD risk loci in a shared intracellular environment downstream of canonical NFkB signaling. Ongoing studies using samples from patients will confirm genotype-dependent activity of NFkB at AD risk variants.
